Autologous and heterologous blood transfusion in head and neck cancer surgery.

Publication/Presentation Date

8-1-1999

Abstract

OBJECTIVE: To determine if the use of autologous blood ameliorates the increased risk for cancer recurrence that has been associated with perioperative blood transfusion.

DESIGN: Retrospective medical record review.

SETTING: Tertiary care hospital.

PATIENTS: One hundred sixty-five consecutive patients with stages II to IV squamous cell carcinoma of the head and neck treated surgically at a university hospital from January 1, 1989, through December 31, 1994.

MAIN OUTCOME MEASURES: We evaluated the impact of perioperative autologous and heterologous blood transfusion and 10 other variables on recurrence. Univariate and multivariate analyses were used.

RESULTS: Heterologous blood recipients had a 59% recurrence rate, whereas those who had received autologous blood or no transfusion had recurrence rates of 33% and 35%, respectively. The following 4 variables had a statistically significant association with recurrence by multivariate analysis: previous treatment of current malignancy (P

CONCLUSION: Autologous blood products should be used during head and neck cancer surgery if possible when transfusion is necessary.

Volume

125

Issue

8

First Page

864

Last Page

868

ISSN

0886-4470

Disciplines

Medicine and Health Sciences

PubMedID

10448732

Department(s)

Department of Surgery, Division of Otolaryngology

Document Type

Article

Link to Full Text

Share

COinS